Boehringer Ingelheim’s glucagon/GLP-1 dual agonist has driven 16.6% weight loss at Week 76 of a phase 3 study. While the ...
Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more ...
The patient death occurred outside the U.S. and was deemed unrelated to Newron Pharmaceuticals’ investigational schizophrenia ...
In late April 2026, Intellia Therapeutics completed a US$180.00 million follow-on offering of 16,744,187 common shares at US$10.75 each, shortly after reporting that its in vivo CRISPR therapy lonvo-z ...
Our AstraZeneca (NASDAQ:AZN) call comes one day after the British drugmaker reported Q1 2026 revenue of $15.29 billion, up 13 ...
Quantum Space has acquired Phase Four’s multi-mode propulsion assets to boost its capability to deliver highly maneuverable, persistent and cost-efficient platforms for national security, civil and ...
The biggest stories of the day delivered to your inbox.
In a statement on Instagram, Kristy James, president and CEO of the Burnaby Hospital and Community Foundation, said that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results